The U.S. Court of Appeals for the Fifth Circuit on Friday temporarily blocked the online sale and mail delivery of the abortion drug mifepristone across the country, restoring in-person screening requirements that the FDA had stripped away under the Biden administration. The ruling marks the most significant legal challenge to abortion access since the Supreme Court overturned Roe v. Wade in 2022.
The decision, handed down Friday afternoon in litigation brought by Louisiana against the Food and Drug Administration, reinstates the requirement that mifepristone be dispensed in person at clinics rather than prescribed via telehealth and shipped through the mail. A unanimous three-judge panel found that Louisiana was "suffering irreparable harm" from the FDA's loosened protocols, the Washington Examiner reported.
The stakes are enormous. Mifepristone is used in nearly two-thirds of the more than 1.1 million abortions performed in the United States each year. Roughly one in four abortions nationally are now prescribed via telehealth, a pipeline AP News described as central to the modern abortion industry's business model. Friday's ruling threatens to shut that pipeline down.
The FDA originally approved mifepristone for commercial use more than twenty years ago. For most of that time, in-person dispensing requirements remained in place. Then, in 2023, the Biden administration's FDA removed those safeguards, a move the Fifth Circuit's opinion characterized as intentionally designed to expand abortion access.
Judge Stuart Kyle Duncan, who was appointed by President Donald Trump in 2018 and authored Friday's opinion, wrote that the FDA's decision had directly undermined state sovereignty in the thirteen states that prohibit elective abortion:
"By ending the in-person dispensing requirement, FDA opened the door for mifepristone to be remotely prescribed to Louisiana women."
Duncan continued, laying out the constitutional collision at the heart of the case:
"Every abortion facilitated by the FDA's action cancels Louisiana's ban on medical abortion and undermines its policy that 'every unborn child is human being from the moment of conception and is therefore, a legal person.'"
That framing matters. It means the court viewed the FDA's regulatory change not as a neutral scientific decision, but as a federal action that functionally nullified the laws of states that had exercised their post-Dobbs authority to restrict abortion. The growing divide among federal appeals courts on questions of executive authority makes this case all the more consequential.
Louisiana built its standing argument on concrete financial damages, not abstract policy disagreements. The state's complaint identified $92,000 in Medicaid costs incurred in 2025 alone to treat just two women who required emergency medical care after complications from mail-order abortion pills.
The court found those costs were not isolated. Duncan noted that "nearly 1,000 women monthly, many of whom are on Medicaid, have mifepristone-induced abortions in Louisiana," and that such costs "will almost certainly continue." Medicaid covers more than 40 percent of Louisiana's population, including three in ten adults, meaning taxpayers bear a significant share of the downstream consequences when things go wrong.
The opinion found that Louisiana had established both "causation and redressability", the legal threshold required to bring the suit, because the FDA's removal of in-person requirements directly enabled pills to flow into a state where abortion is banned.
Louisiana Attorney General Liz Murrill, alongside the Christian legal advocacy group Alliance Defending Freedom, filed the lawsuit against the FDA last fall. The suit demanded reinstatement of the in-person dispensing requirement that had been in place for decades before the Biden-era change.
Earlier this month, a federal district court paused Murrill's lawsuit to give the FDA more time to complete a long-promised safety review of mifepristone. That review had been pledged by Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary during their confirmation hearings last year. But the review has yet to materialize, and Friday's appellate ruling effectively bypassed the district court's patience.
This is not the first time the Fifth Circuit has taken aim at the FDA's mifepristone decisions. In a related 2023 ruling, a three-judge panel found the agency had "failed to address several important concerns about whether the drug would be safe for the women who use it," as Judge Jennifer Walker Elrod wrote. That earlier decision rolled back FDA actions from both 2016 and 2021 that had expanded access, including banning mail distribution and limiting the drug's use to seven weeks of pregnancy.
Those 2023 restrictions never took effect, however, because the Supreme Court issued a stay preserving the status quo while the justices considered whether to take up the case. The high court ultimately declined to rule on the merits, finding the plaintiffs in that round lacked standing, a gap Louisiana's new suit was specifically designed to close.
The internal dynamics at the Supreme Court will likely determine whether Friday's ruling survives, given that the justices have already shown a willingness to intervene in mifepristone litigation on an emergency basis.
Murrill celebrated the decision in a statement, framing it as the end of what she called a lawless chapter in federal drug regulation. The attorney general said she looked forward "to continuing to defend women and babies as this case continues," and added sharply:
"The Biden abortion cartel facilitated the deaths of thousands of Louisiana babies (and millions in other states) through illegal mail-order abortion pills. Today, that nightmare is over."
Sen. Bill Cassidy, the Louisiana Republican and anti-abortion advocate who faces a competitive primary this election cycle, posted on X Friday evening. Cassidy stated:
"Women in Louisiana have been coerced into taking these drugs shipped in from out of state without medical oversight. This ruling is a victory for mothers and babies in Louisiana."
On the other side, ACLU lawyer Julia Kaye warned the ruling would have sweeping consequences. "This is going to affect patients' access to abortion and miscarriage care in every state in the nation," Kaye told AP News.
The ruling's practical reach depends on what comes next at the Supreme Court. In the 2023 round of mifepristone litigation, the justices stayed the Fifth Circuit's restrictions while the case moved through the system. Whether they do so again, and whether they ultimately take the case, will determine whether in-person dispensing requirements hold or collapse.
Alliance Defending Freedom, which has driven much of the legal strategy against the FDA's mifepristone decisions, declared the ruling a vindication. Erin Hawley of ADF said the Fifth Circuit "rightly required the FDA to do its job and restore crucial safeguards for women and girls, including ending illegal mail-order abortions," the Washington Free Beacon reported.
Planned Parenthood's Alexis McGill Johnson countered that the case "makes it clear that mifepristone's approval is very much still at risk, as is the FDA's independence." But that framing conflates two different questions. Nobody on the Fifth Circuit panel revoked mifepristone's approval. The court's concern was narrower and more grounded: the FDA stripped away safety protocols without adequate justification, and states bore the cost.
Meanwhile, the promised federal safety review of mifepristone, the one Kennedy and Makary pledged during their confirmation hearings, remains incomplete. The district court gave the FDA extra time to finish it. The Fifth Circuit, evidently, was not willing to wait.
The broader pattern of high-stakes judicial clashes reaching the Supreme Court suggests this case will land on the justices' docket sooner rather than later. And the outcome will set a precedent not just for abortion policy, but for how much latitude federal agencies have to rewrite the rules without congressional authorization.
Thirteen states now ban elective abortion. Mifepristone, shipped through the mail with no in-person screening, was the workaround. The Biden FDA built that workaround deliberately, and the Fifth Circuit said so explicitly. The court did not invent the conflict, the agency created it by removing safeguards that had been in place for two decades and hoping no one with standing would sue.
Louisiana sued. Louisiana had standing. And on Friday, Louisiana won.
The legal question of whether courts will continue to hold federal agencies accountable when they exceed their authority is one of the defining fights of this era. Friday's ruling is a clear signal that at least one circuit is not willing to let bureaucratic convenience override state law and patient safety.
When a federal agency quietly dismantles the safeguards on a powerful drug to advance a political agenda, and states have to pick up the tab when women end up in emergency rooms, calling that "expanded access" doesn't make it good policy. It makes it a liability someone else has to pay for.
